Compare Ascendis Pharma A/S (ASND) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs United Microelectronics Corp — how do they compare? Ascendis Pharma A/S trades at $254.89 (market cap $16.67B), while United Microelectronics Corp trades at $19.47 (market cap $47.81B). The key difference: United Microelectronics Corp is far larger — about 2.9× Ascendis Pharma A/S's market cap, and United Microelectronics Corp pays a 2.12% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | UMC | |
|---|---|---|
Market Cap | $16.67B | $47.81B |
Sector | Health | Technology |
52-Week High | $277.18 | $28.02 |
52-Week Low | $189.74 | $6.58 |
Enterprise Value | $17.04B | $44.93B |
Dividend Yield | — | 2.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.
ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.
UMC trades at $19.40, up 3.25% with a neutral technical signal. The company reported strong Q2 2026 earnings, beating estimates with $0.54 EPS, and announced fab expansions in Singapore and Taiwan to meet AI demand. Revenue growth is projected to rise to $250.7 billion in 2026, with net income margin improving to 32.75%. Cash flow turned positive in 2025 at $5.66 billion, supporting strategic investments.
Outlook is positive due to AI-driven demand and operational execution, but risks include competitive pressures and capital expenditure volatility. Analysts show mixed sentiment with 26.7% buy ratings, highlighting cautious optimism amid expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
